Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagus Cancer Clear all
Active, not recruiting No phase listed Observational

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

NCT05717998
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Orange, California • New Haven, Connecticut • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Methylene Blue Chromoendoscopy in Barrett's Esophagus

NCT00587652
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

NCT00021320
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Esomeprazole, Lansoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 2 Interventional

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

NCT03592407
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacodynamic Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • West Covina, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

NCT00701857
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, Pemetrexed, radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

NCT00193128
View directory record Official record
Conditions
Esophagus Cancer
Interventions
Oxaliplatin, Docetaxel, Capecitabine, Radiation therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

NCT00354679
View directory record Official record
Conditions
Esophageal Cancer
Interventions
bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Patients Receiving High-Dose Rate Brachytherapy

NCT00924027
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Interventions
High Dose Radiation (HDR) Brachytherapy, MRI, CT, PET Scan
Radiation · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

NCT00005876
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

NCT01733147
View directory record Official record
Conditions
Barrett's Esophagus, Obesity
Interventions
Omega-3 polyunsaturated fatty acids, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Not applicable Interventional

Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery

NCT02843750
View directory record Official record
Conditions
Cancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer, Esophagus Cancer, Esophagus Neoplasm, Neoplasms, Esophageal
Interventions
Inspiratory Muscle Training-Rehabilitation, Questionnaires
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population

NCT05778851
View directory record Official record
Conditions
Barrett Esophagus
Interventions
EsoGuard result
Device
Lead sponsor
Lucid Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Esophageal Cancer Tissue Banking

NCT01780961
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System

NCT02033070
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Radiation Therapy and Cardiac Enzymes

NCT00777751
View directory record Official record
Conditions
Tumor
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

NCT07700420
View directory record Official record
Conditions
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Interventions
PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

NCT00601692
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

NCT00259987
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Lapatinib (GW572016) oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

NCT06906887
View directory record Official record
Conditions
Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer
Interventions
Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation, Pulsed Low-Dose-Rate (PLDR) Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

NCT00900419
View directory record Official record
Conditions
Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
Interventions
immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology, biopsy
Other · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1 Interventional

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

NCT03094884
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Pulsed Low Dose Radiation, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 17, 2026, 5:15 AM EDT